Pfizer, Inc. Free Cash Flow 2007–2025
Pfizer, Inc. reported $9.07B of free cash flow for fiscal 2025. That was 7.7% lower than fiscal 2024. Compared with fiscal 2020, the change was -25.5%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $9.07B | -7.7% |
| FY 2024 | $9.84B | +105.2% |
| FY 2023 | $4.79B | -81.6% |
| FY 2022 | $26.03B | -12.8% |
| FY 2021 | $29.87B | +145.3% |
| FY 2020 | $12.18B | +15.5% |
| FY 2019 | $10.54B | -23.8% |
| FY 2018 | $13.84B | -6.8% |
| FY 2017 | $14.85B | +3.3% |
| FY 2016 | $14.37B | +8.1% |
| FY 2015 | $13.29B | -16.3% |
| FY 2014 | $15.88B | -3.6% |
| FY 2013 | $16.48B | +6.9% |
| FY 2012 | $15.42B | -17.0% |
| FY 2011 | $18.58B | +86.9% |
| FY 2010 | $9.94B | -35.4% |
| FY 2009 | $15.38B | -7.0% |
| FY 2008 | $16.54B | +44.1% |
| FY 2007 | $11.47B | — |
Source: Pfizer, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open PFE 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Pfizer, Inc. reported $9.07B of free cash flow for fiscal 2025. That was 7.7% lower than fiscal 2024. Compared with fiscal 2020, the change was -25.5%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Pfizer, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freePfizer, Inc. — frequently asked questions
What is Pfizer, Inc.'s free cash flow?
Pfizer, Inc. (PFE) reported free cash flow of $9.07B for fiscal year 2025, per its SEC filings.
How has Pfizer, Inc.'s free cash flow changed over time?
Between fiscal 2007 and 2025, PFE's free cash flow declined at roughly 1.3% per year (compound annual rate), from $11.47B to $9.07B.
Where does this data come from?
Figures are computed from Pfizer, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.